The reported statements, read against the company's own industry.
Financials view
Market Capitalization
722.84MEUR
792.87M · vs all stocks (USD)
Updated Oct 25, 2026
Revenue (TTM)
2.46MEUR
2.69M · vs all stocks (USD)
Updated Oct 25, 2026
Profit Margin
0.00%
vs Biotechnology peers
Provider-reported. Net Income (TTM) ÷ Revenue (TTM) on this page gives -10086.44%.Updated Oct 25, 2026
Beta
0.9990x
vs all stocks
Updated Oct 25, 2026
52-Week Change
-1.29%
vs all stocks
Updated Oct 25, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 25, 2026
Market Capitalization
722.84MEUR
792.87M · vs all stocks (USD)
Updated Oct 25, 2026
Enterprise Value
695.68MEUR
763.08M · vs all stocks (USD)
Updated Oct 25, 2026
Forward P/E
-5.14x
vs Biotechnology peers
Updated Oct 25, 2026
Price to Book (MRQ)
12.24x
vs Biotechnology peers
Updated Oct 25, 2026
Enterprise to Revenue
283.26x
vs Biotechnology peers
Updated Oct 25, 2026
Enterprise to EBITDA
-4.67x
vs Biotechnology peers
Updated Oct 25, 2026
Profit Margin
0.00%
vs Biotechnology peers
Provider-reported. Net Income (TTM) ÷ Revenue (TTM) on this page gives -10086.44%.Updated Oct 25, 2026
Return on Assets (TTM)
-42.69%
vs Biotechnology peers
Updated Oct 25, 2026
Return on Equity (TTM)
-989.05%
vs Biotechnology peers
Updated Oct 25, 2026
Revenue (TTM)
2.46MEUR
2.69M · vs all stocks (USD)
Updated Oct 25, 2026
Revenue per Share (TTM)
0.0090EURUpdated Oct 25, 2026
Quarterly Revenue Growth
-76.70%
vs Biotechnology peers
Updated Oct 25, 2026
Gross Profit (TTM)
1.92MEUR
2.11M · vs all stocks (USD)
Updated Oct 25, 2026
EBITDA (TTM)
-149.06MEUR
-163.50M · vs all stocks (USD)
Updated Oct 25, 2026
Net Income (TTM)
-247.72MEUR
-271.72M · vs all stocks (USD)
Updated Oct 25, 2026
Operating Cash Flow (TTM)
-96.60MEUR
-105.96M · vs all stocks (USD)
Updated Oct 25, 2026
Levered Free Cash Flow (TTM)
-116.12MEUR
-127.37M · vs all stocks (USD)
Updated Oct 25, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 25, 2026
Trailing Annual Dividend Rate
0.00EURUpdated Oct 25, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 25, 2026
Revenue
4.48MEURFY2025 · Dec 31, 2025
Operating Income
-132.88MEUR
-145.76M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-354.11MEURFY2025 · Dec 31, 2025
Income Tax Expense
22.00KEURFY2025 · Dec 31, 2025
Net Income
-354.13MEURFY2025 · Dec 31, 2025
EBIT
-320.55MEURFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-127.12MEURFY2025 · Dec 31, 2025
Research & Development
87.04MEURFY2025 · Dec 31, 2025
Selling, General & Administrative
53.89MEURFY2025 · Dec 31, 2025
Other Operating Expenses
-3.82MEURFY2025 · Dec 31, 2025
Non-operating Interest Income
2.94MEURFY2025 · Dec 31, 2025
Non-operating Interest Expense
33.56MEURFY2025 · Dec 31, 2025
EPS (Basic)
-1.90EURFY2025 · Dec 31, 2025
EPS (Diluted)
-1.90EURFY2025 · Dec 31, 2025
Basic Shares Outstanding
186.80MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
186.80MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-354.14MEURFY2025 · Dec 31, 2025
Operating Cash Flow
-114.09MEURFY2025 · Dec 31, 2025
Free Cash Flow
-114.34MEURFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
99.31MEURFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-354.14MEURFY2025 · Dec 31, 2025
Depreciation & Amortization
3.22MEURFY2025 · Dec 31, 2025
Deferred Taxes (CF)
-2.30MEURFY2025 · Dec 31, 2025
Stock-based Compensation
26.77MEURFY2025 · Dec 31, 2025
Other Non-cash Items
213.14MEURFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
850.00KEURFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-1.64MEURFY2025 · Dec 31, 2025
Capital Expenditures
-247.00KEURFY2025 · Dec 31, 2025
Purchase of Investments
-132.94MEURFY2025 · Dec 31, 2025
Other Investing Activity
-1.00KEURFY2025 · Dec 31, 2025
Net Investing Cash Flow
-133.19MEURFY2025 · Dec 31, 2025
Long-term Debt Issuance
0.00EURFY2025 · Dec 31, 2025
Long-term Debt Payments
-5.98MEURFY2025 · Dec 31, 2025
Common Dividends Paid
0.00EURFY2025 · Dec 31, 2025
Other Financing Charges
-17.13MEURFY2025 · Dec 31, 2025
Net Financing Cash Flow
183.33MEURFY2025 · Dec 31, 2025
Shares Outstanding
193.18MSharesUpdated Oct 25, 2026
Float Shares
162.98MSharesUpdated Oct 25, 2026
% Held by Insiders
12.58%
vs all stocks
Updated Oct 25, 2026
% Held by Institutions
50.07%
vs all stocks
Updated Oct 25, 2026
Total Cash (MRQ)
166.13MEUR
182.22M · vs all stocks (USD)
Updated Oct 25, 2026
Total Cash per Share (MRQ)
0.7030EURUpdated Oct 25, 2026
Total Debt (MRQ)
138.79MEUR
152.24M · vs all stocks (USD)
Updated Oct 25, 2026
Total Debt to Equity (MRQ)
2.35x
vs Biotechnology peers
Updated Oct 25, 2026
Current Ratio (MRQ)
3.81x
vs Biotechnology peers
Updated Oct 25, 2026
Book Value per Share (MRQ)
0.2500EURUpdated Oct 25, 2026
Total Assets
249.51MEUR
273.69M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
244.47MEURFY2025 · Dec 31, 2025
Total Liabilities
278.03MEURFY2025 · Dec 31, 2025
Total Non-current Assets
5.04MEURFY2025 · Dec 31, 2025
Total Non-current Liabilities
200.66MEURFY2025 · Dec 31, 2025
Total Current Liabilities
77.38MEURFY2025 · Dec 31, 2025
Cash
16.68MEURFY2025 · Dec 31, 2025
Cash Equivalents
82.63MEURFY2025 · Dec 31, 2025
Cash & Cash Equivalents
99.31MEURFY2025 · Dec 31, 2025
Other Short-term Investments
131.56MEURFY2025 · Dec 31, 2025
Accounts Receivable
2.02MEURFY2025 · Dec 31, 2025
Inventory
0.00EURFY2025 · Dec 31, 2025
Accounts Payable
26.02MEURFY2025 · Dec 31, 2025
Short-term Debt
32.31MEURFY2025 · Dec 31, 2025
Deferred Revenue
0.00EURFY2025 · Dec 31, 2025
Other Current Liabilities
1.00KEURFY2025 · Dec 31, 2025
Long-term Debt
27.55MEURFY2025 · Dec 31, 2025
Other Non-current Liabilities
52.84MEURFY2025 · Dec 31, 2025
Common Stock (Book)
1.93MEURFY2025 · Dec 31, 2025
Retained Earnings
-354.14MEURFY2025 · Dec 31, 2025
Total Shareholders' Equity
-28.52MEUR
-31.29M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
2.57EURUpdated Oct 25, 2026
52-Week High
6.20EURUpdated Oct 25, 2026
52-Week Change
-1.29%
vs all stocks
Updated Oct 25, 2026
Beta
0.9990x
vs all stocks
Updated Oct 25, 2026
50-Day MA
3.41EURUpdated Oct 25, 2026
200-Day MA
4.22EURUpdated Oct 25, 2026
Avg 10-Day Volume
538.91KSharesUpdated Oct 25, 2026
Avg 30-Day Volume
629.64KSharesUpdated Oct 25, 2026
Diluted EPS (TTM)
-0.5400EURUpdated Oct 25, 2026
Other Income / Expense
-190.55MEURFY2025 · Dec 31, 2025
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -5337.3%, lower than 95% of its Biotechnology peers (median -30.3%)Significant